Some of Thursday's midday movers:» Read More
PARIS, Oct 2- Sanofi's experimental pill to treat Gaucher disease, a rare inherited condition, has met its main goal in a late-stage trial, the French drugmaker said on Tuesday.
CAC-40 futures are 0.7 percent lower at 0620 GMT FRANCE TELECOM. The oil services company said on Tuesday it has signed a lump-sum contract with Murphy Exploration& Production Company for the development of an offshore field in the Gulf of Mexico.
LONDON, Oct 1- European shares rebounded from three-week lows on Monday in a technical rally, with price dips and the unsurprising results of a Spanish bank stress test luring investors into the market, but analysts said the bounce was unsustainable. fiscal cliff "of scheduled tax hikes and government spending cuts as well as the situation in Spain.
Christopher Viehbacher, Sanofi CEO, discusses his company's acquisition of Genzyme and where he sees further deals in the pharmaceutical industry.
Chris Viehbacher, CEO, Sanofi says the firm has been built so that it could grow without having to rely on the research and development of patents.
Sanofi CEO Christopher Viehbacher discusses his company's $20 billion acquisition of Genzyme and other opportunities he sees in the pharmaceutical market.
Mad Money's Cramer, explains why Sanofi-Aventis is his favorite medical breakthrough stock, saying it has excellent management; its growth platforms are working; and it supplies a juicy dividend.
Sanofi and two venture capital firms announced Tuesday that they are investing in bio-tech start-up "Warp Drive," with Oliver Fetzer, Cerulean Pharma Inc. CEO, and Terry McGuire, Polaris Venture Partners.
A check up on the health care sector, with Chris Viehbacher, Sanofi-Aventis CEO, who shares his outlook for 2012.
Chris Viehbacher, CEO of Sanofi, told CNBC, "we have leading positions in nice long life assets, in animal health, in vaccines in emerging markets in diabetes and those will continue to grow because the underlying dynamics are there and that leading position, so I am pretty confident about the medium term outlook."
Sanofi announced it won a patent litigation case over its eloxation cancer drug, with Christopher Viehbacher, Sanofi CEO, and Mad Money host Jim Cramer.
Chris Viehbacher, Sanofi-Aventis CEO discusses President Obama's healthcare plan and future plans for his company.
Sanofi-Aventis concludes its Genzyme acquisition and shares of Best Buy may show a sign of electronics chains losing power, reports CNBC's David Faber.
The Food and Drug Administration rejected another new diet pill on Thursday, the latest setback in the quest to develop treatments for overweight Americans amid the nation’s obesity epidemic.
U.S. drugs giant Abbott Laboratories said it would stop launching new medicines in Thailand in protest at the army-backed government's move to override international drug patents.